BridgeMD
New treatment option for Gastrointestinal Cancer
Official title Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
ClinicalTrials.gov ID: NCT06596694
What this study is testing
What is Patritumab deruxtecan?
Patritumab deruxtecan is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for gastrointestinal cancer.
Also referred to as MK-1022, HER3-DXd.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- The main include but are not limited to the following:
- Has one of the following cancers:
- Unresectable or metastatic colorectal cancer.
- Advanced and/or unresectable biliary tract cancer (BTC)
- Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
You likely can't join if
- The main exclusion criteria include but are not limited to the following:
- Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or...
- Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
- Has evidence of any leptomeningeal disease
- Has clinically significant corneal disease
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
See the full eligibility criteria
- The main include but are not limited to the following:
- Has one of the following cancers:
- Unresectable or metastatic colorectal cancer.
- Advanced and/or unresectable biliary tract cancer (BTC)
- Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
- Locally advanced unresectable or metastatic gastroesophageal cancer
- Has received prior therapy for the cancer.
- Has recovered from any side effects due to previous cancer treatment
- The main exclusion criteria include but are not limited to the following:
- Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard...
- Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
- Has evidence of any leptomeningeal disease
- Has clinically significant corneal disease
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
The study team makes the final eligibility decision.
Where it's taking place
- Santa Monica, California, United States
- Aurora, Colorado, United States
- Washington D.C., District of Columbia, United States
- Gainesville, Florida, United States
- Miami Beach, Florida, United States
- Marietta, Georgia, United States
- Chicago, Illinois, United States
- Reno, Nevada, United States
- Mineola, New York, United States
- New York, New York, United States
- Temple, Texas, United States
- Roanoke, Virginia, United States
- Madison, Wisconsin, United States
- Sydney, New South Wales, Australia
- Melbourne, Victoria, Australia
- Mount Pleasant, Western Australia, Australia
- Halifax, Nova Scotia, Canada
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- Santiago, Region M. de Santiago, Chile
+ 33 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Santa Monica, California, United States; Aurora, Colorado, United States; Washington D.C., District of Columbia, United States; Gainesville, Florida, United States; Miami Beach, Florida, United States; Marietta, Georgia, United States and 47 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.